Peter Partee, MD
Family Medicine · Laurens, SCNPI 1912945841
Payments from drug & device makers
Across 513 payments — averaging $34.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$10K
- AbbVie$2K
- Novo Nordisk$848
- AstraZeneca$738
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$457
- Lilly USA, LLC$449
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$8,94350%
- Travel & lodging$6294%
- Food & beverage$8,18046%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 23 | $10,140 |
| AbbVie(2 entities) | 105 | $1,569 |
| Novo Nordisk | 64 | $848 |
| AstraZeneca | 36 | $738 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $457 |
| Lilly USA, LLC | 31 | $449 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $448 |
| GSK | 29 | $413 |
| Pfizer | 25 | $330 |
| Abbott | 13 | $237 |
| Novartis | 15 | $231 |
| Otsuka America Pharmaceutical, Inc. | 10 | $218 |
| Boehringer Ingelheim | 13 | $177 |
| Exact Sciences | 12 | $173 |
| Bayer | 10 | $157 |
| Amgen | 9 | $134 |
| Phathom Pharmaceuticals, Inc. | 8 | $120 |
| Astellas Pharma US Inc | 7 | $119 |
| Sanofi-aventis U.S. LLC | 8 | $115 |
| Corcept Therapeutics | 5 | $95 |
| Daiichi Sankyo Inc. | 5 | $87 |
| Merck | 5 | $73 |
| Lundbeck LLC | 3 | $62 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Abiomed | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Medtronic | 1 | $26 |
| Johnson & Johnson | 2 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Inari Medical, Inc. | 1 | $23 |
| Tris Pharma Inc | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Promius Pharma LLC | 1 | $12 |
| Organon | 1 | $8 |
| Dynavax Technologies Corporation | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$9,909
- DEXCOM STELO GLUCOSE BIOSENSOR$6,778
- BREZTRI$242
- FARXIGA$242
- AIRSUPRA$242
How this compares
$17,752 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 178 | $184,499 |
| OzempicSemaglutide | 157 | $159,529 |
| RybelsusSemaglutide | 64 | $94,032 |
| EliquisApixaban | 108 | $85,654 |
| MounjaroTirzepatide | 60 | $80,515 |
| LinzessLinaclotide | 77 | $56,447 |
| FarxigaDapagliflozin Propanediol | 70 | $48,141 |
| TrulicityDulaglutide | 35 | $41,290 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $32,987 |
| MyrbetriqMirabegron | 45 | $25,252 |
| JanuviaSitagliptin Phosphate | 22 | $24,169 |
| KerendiaFinerenone | 32 | $23,370 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $22,899 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $17,394 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $17,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $848 | $253,561221 claims |
| Boehringer IngelheimJardiance, Synjardy, Stiolto Respimat | $177 | $197,713204 claims |
| Lilly USA, LLCMounjaro, Trulicity | $449 | $121,80495 claims |
| PfizerEliquis, Premarin | $330 | $92,222122 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $738 | $63,72599 claims |
| AbbVieLinzess | $1,569 | $56,44777 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $413 | $41,32946 claims |
| MerckJanuvia, Janumet Xr | $73 | $30,64534 claims |
| Astellas Pharma US IncMyrbetriq | $119 | $25,25245 claims |
| BayerKerendia | $157 | $23,37032 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $457 | $9,25017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Laurens
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.